Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengdekang capsule is a Traditional Chinese Medicine (TCM) preparation developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is specifically formulated to treat patients with advanced non-small cell lung cancer (NSCLC) who present with qi-yin deficiency syndrome, a common TCM diagnostic pattern characterized by fatigue, shortness of breath, and dry cough. The capsule is investigated as an adjunct to first-line systemic treatments, including platinum-based chemotherapy and immune checkpoint inhibitors. Its therapeutic goals include improving patient quality of life, reducing the side effects of conventional therapies, and potentially synergizing with immunotherapy to improve clinical outcomes. As a hospital-made preparation, it represents an integration of traditional herbal medicine with modern oncological care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhengdekang capsule.